Rare somatic p53 mutation identified in breast cancer: A case report

Tumor Biology

Volumn 22, Issue 2, 2001, Pages 59-66

  Šmardová, Jana ^a   Nemajerova A ^a   Trbusek M ^b   Vagunda, V ^a   Kovarik J ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b Research Institute of Child Health Brno   (Czech Republic)

Author keywords

FASAY; Oligomerization domain; p53; Somatic mutation

Indexed keywords

ARGININE; CYSTEINE; PROTEIN P53;

AMINO ACID SUBSTITUTION; ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; DATA BASE; DNA BINDING; DNA REPAIR; EXON; FRAMESHIFT MUTATION; GENETIC CODE; IMMUNOPRECIPITATION; LEUKOCYTE; MISSENSE MUTATION; OLIGOMERIZATION; PRIORITY JOURNAL; SOMATIC MUTATION; STOP CODON; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

EID: 0035183777     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050597     Document Type: Article

References (45)

1. Database and software for the analysis of mutations in the human p53 gene
2. Database of p53 gene somatic mutations in human tumors and cell lines: Update compilation and future prospects
3. Evolutionary conservation and somatic mutation hotspot maps of p53: Correlation with p53 protein structural and functional features
4. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
5. The 1995 Walter Hubert Lecture - Molecular epidemiology of human cancer: Insights from the mutational analysis of the p53 tumour-Suppressor gene
6. Carcinogens leave fingerprints
7. Novel p53 mutants selected in BRCA-Associated tumours which dissociate transformation suppression from other wild-type p53 function
8. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
9. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains
10. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer
11. Germ-Line splicing mutation of the p53 gene in a cancer prone family
12. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family
13. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assay in yeast
14. Mutational analysis of the carboxy-Terminal portion of p53 using both yeast and mammalian cell assay in vivo
15. A simple p53 functional assay for screening cell lines, blood, and tumors
16. Screening patients for heterozygous p53 mutations using a functional assay in yeast
17. p53 protein alterations in human testicular cancer including preinvasive intralobular germ-cell neoplasia
18. An immunochemical analysis of human p53: New monoclonal antibodies and epitope mapping using recombinant p53
19. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein
20. Precise epitope mapping of the transformation-associated protein p53
21. Activating mutations in p53 produce a common conformation effect. A monoclonal antibody specific for the mutant form
22. Monoclonal antibodies specific for simian virus 40 tumour antigen
23. Analysis of p53 expression in human tumors: An antibody raised against human p53 expressed in E. coli
24. Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library
25. A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40
26. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma
27. p53 gene mutation inside and outside of exons 5-8: The patterns differ in breast and other cancers
28. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies
29. p53 in prostate cancer: Frequent expressed transition mutations
30. Reciprocal relationship between the tumor suppressor p53 and BAX in primary colorectal cancers
31. Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients
32. Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: Increased frequency and different spectrum of mutations from primary tumors
33. Loss of function and p53 protein stabilization
34. New insights into p53 function from structural studies
35. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in Li-Fraumeni-like family
36. Abnormal expression of wild-type p53 protein in normal cells of a cancer family patient
37. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members
38. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-Like syndrome
39. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity
40. The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth
41. How p53 binds DNA as a tetramer
42. A leucine-Rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking
43. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser 20, requires tetramerization
44. DNA damage activates p53 through a phosphorylation-acetylation cascade
45. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2